Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

D'ALESSANDRO, Natale
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.709
EU - Europa 3.853
AS - Asia 981
SA - Sud America 11
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 11.570
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.699
IT - Italia 1.379
UA - Ucraina 727
FI - Finlandia 707
CN - Cina 611
IE - Irlanda 271
DE - Germania 199
SG - Singapore 171
GB - Regno Unito 168
SE - Svezia 114
RU - Federazione Russa 94
FR - Francia 78
TR - Turchia 66
IN - India 45
BE - Belgio 31
IR - Iran 31
KR - Corea 28
RO - Romania 27
CH - Svizzera 11
CZ - Repubblica Ceca 11
PL - Polonia 9
AT - Austria 7
EU - Europa 6
HK - Hong Kong 6
NL - Olanda 6
AL - Albania 5
BR - Brasile 5
CA - Canada 5
JP - Giappone 5
LB - Libano 5
MY - Malesia 5
MX - Messico 4
TN - Tunisia 4
CI - Costa d'Avorio 3
ES - Italia 3
PE - Perù 3
BG - Bulgaria 2
CL - Cile 2
GR - Grecia 2
PK - Pakistan 2
TH - Thailandia 2
UZ - Uzbekistan 2
AR - Argentina 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GH - Ghana 1
HR - Croazia 1
KH - Cambogia 1
PA - Panama 1
VN - Vietnam 1
Totale 11.570
Salva come PNG Salva come JPEG
Città #
Fairfield 771
Chandler 579
Ashburn 529
Woodbridge 470
Ann Arbor 427
Wilmington 414
Houston 402
Jacksonville 391
Seattle 288
Dublin 268
Palermo 255
Cambridge 248
Des Moines 218
Medford 206
Nanjing 164
Princeton 130
Singapore 127
Boardman 111
Tulsa 101
Altamura 89
Dearborn 85
Beijing 76
Lawrence 61
New York 61
Milan 53
Izmir 50
Shenyang 50
San Diego 47
Nanchang 46
Hebei 44
Santa Clara 40
Changsha 36
Venice 35
Falls Church 34
Rome 34
Verona 29
Brussels 28
Jiaxing 27
Seongnam 27
London 26
Naples 26
Helsinki 25
Ludwigshafen am Rhein 23
Ningbo 22
San Mateo 22
Napoli 21
Jinan 20
Guangzhou 18
Tianjin 17
Auburn Hills 15
Kumar 15
Zhengzhou 15
Bremen 14
Saint Petersburg 13
Los Angeles 12
San Paolo di Civitate 12
Bari 11
Orange 11
Haikou 10
Norwalk 10
Pune 10
Redwood City 10
Taizhou 10
Turin 10
Bologna 9
Hangzhou 9
Kunming 9
Council Bluffs 8
Dallas 7
Durham 7
Moscow 7
Padova 7
Salerno 7
Sanayi 7
Tehran 7
Torino 7
Chicago 6
Shanghai 6
Taiyuan 6
Washington 6
Atlanta 5
Bacoli 5
Brescia 5
Florence 5
Genoa 5
Isfahan 5
Lanzhou 5
Munich 5
Tappahannock 5
Andover 4
Carini 4
Corato 4
Düsseldorf 4
Hong Kong 4
Kilburn 4
Louisville 4
Mountain View 4
Olomouc 4
Paceco 4
Parma 4
Totale 7.653
Salva come PNG Salva come JPEG
Nome #
Yin Yang 1 and Raf-1 Kinase Inhibitory Protein Status in Hepatocellular Carcinoma: Future Perspectives 181
BRONJ in patients with rheumatoid arthritis: A multicenter case series 181
Induction of Apoptosis and Chemosensitization by the Histone Deacetylase Inhibitor Trichostatin in Hepatocellular Carcinoma Cells: Molecular Analysis and RKIP Levels 173
Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. 164
Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer 163
Farmaci antimicrotubulari 162
Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein Ratio in Hepatocellular Carcinoma 161
Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells 158
Expression of the IAPs in multidrug resistant tumor cells 155
ANTITUMOR EFFECTS OF CURCUMIN, ALONE OR IN COMBINATION WITH CISPLATIN OR DOXORUBICIN, ON HUMAN HEPATIC CANCER CELLS. ANALYSIS OF THEIR POSSIBLE RELATIONSHIP TO CHANGES IN NF-KB ACTIVATION LEVELS AND IAP GENE EXPRESSION 154
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells 153
Epigenetic changes and nuclear factor-κB activation, but not microRNA-224, downregulate Raf-1 kinase inhibitor protein in triple‑negative breast cancer SUM 159 cells 150
Analysis of Possible Mechanisms Accounting for Raf-1 Kinase Inhibitor Protein Downregulation in Hepatocellular Carcinoma 145
Antitumor effects of curcumin and structurally beta-diketone modified analogs on multidrug resistant cancer cells 145
Multifactorial nature of hepatocellular carcinoma drug resistance: Could plant polyphenols be helpful? 141
Sex hormones and risk of liver tumor 139
Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist. 135
Chemioterapici antibatterici 132
NF-kB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines 132
The antitumor activities of curcumin and its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 brest cancer cell line: Analysis of the possible molecular basis. 132
Commentary. Regulation of drug and immune resistance by YY1 in cancer. 132
Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. 131
Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors 130
Fluoroquinolone-induced liver injury: three new cases and a review of the literature. 128
Unusual high dose of tacrolimus in liver transplant patient, a case report. 126
Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors 125
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study 125
NF-kB Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers 125
Chemotherapy-induced cardiotoxicity: role of the conventional echocardiography and the Tissue Doppler 124
Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. 120
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells 120
Pro-oxidant and antitumor effects of curcumin and N-ethylmaleimide in the HA22T/VGH model Overt hepatocellular carcinoma. 119
Aspetti etici e controllo di gestione dei farmaci antibiotici antibatterici 118
Farmacovigilanza in oncologia: la nostra esperienza nel "Centro di consulenza ed informazione sugli effetti tossici da farmaci antitumorali e sulle ADR in pazienti neoplastici" della Regione Sicilia 117
Uso degli inibitori di pompa protonica in un Policlinico Universitario 116
Meccanismi di resistenza ai farmaci antitumorali 116
Frequent alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein ratio in hepatocellular carcinoma 113
Lack of nucleophilic addition in the isoxazole and pyrazole diketone modified analogs of curcumin; implications for their antitumor and chemosensitizing activities. 112
Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients 112
Pharmacokinetic interaction between tacrolimus and corticosteroids in liver transplant patients 111
Induction of apoptosis by arachidonic acid in human retinoblastoma Y79 cells: involvement of oxidative stress 110
Potentiation of the Antitumor Effects of Both Selective Cyclooxygenase-1 and Cyclooxygenase-2 Inhibitors in Human Hepatic Cancer Cells by Inhibition of the MEK/ERK Pathway 110
Effetti della curcumina e di suoi analoghi modificati al frammento beta-dichetone in cellule tumorali multifarmacoresistenti. 109
"Antitumor effects of the novel NF-kB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production”. 107
Antitumor Effects of Dehydroxymethylepoxyquinomicin, a Novel Nuclear Factor-kappa B Inhibitor, in Human Liver Cancer Cells Are Mediated through a Reactive Oxygen Species-Dependent Mechanism 104
The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients 104
Potential Therapeutic Applications of MDA-9/Syntenin-NF-κB-RKIP Loop in Human Liver Carcinoma 103
Farmaci antimicrotubulari. 102
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: Synthesis and biological evaluation of valproic esters of 3’-C-methyladenosine 102
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth 101
Rash and multiorgan dysfunction following lamotrigine: could genetic be involved? 101
USE OF HERBAL REMEDIES AMONG CANCER AND TRANSPLANT PATIENTS IN THE TOWN OF PALERMO, SICILY 99
Resistance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis 96
Induction of apoptosis by the adenosine derivative IB-MECA in parental or multidrug-resistant HL-60 leukemia cells: possibile relationship to the effects on inhibitor of apoptosis protein levels 96
Farmaci inibitori delle topoisomerasi 96
Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of β-catenin and inhibition of β-catenin-mediated transactivation 95
The NF-kB inhibitors curcumin and DHMEQ exert antitumor synergy with cisplatin in hepatic cancer cells. Analysis of relationship to IL-6 production. 94
Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction. 94
Significance of autologous interleukin 6 production in the HA22T/VGH model of hepatocellular carcinoma 93
Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma 92
Altered Yin Yang 1/RAF-1 kinase inhibitory protein ratio as a possible molecular marker and therapeutic target in hepatocellular carcinoma 90
Findings of osteonecrosis of the jaw under combined bisphosphonate and antiangiogenic therapies: an emergent problem? 90
The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients 87
Terapia farmacologica in odontoiatria pediatrica 86
Aderenza alle linee guida sulla profilassi antibiotica delle infezioni della ferita chirurgica nel Policlinico Universitario "P. Giaccone" di Palermo 86
Alteration of signaling pathways in hepatocellular carcinoma: identification of new pharmacological targets and possible prognosis markers. 85
Cyclooxygenase-2 expression in chronic liver disease and hepatocellular carcinoma: an immunohistochemical study 84
Potential role of the natural multi-targeted agent curcumin in the treatment of oral diseases. 82
Expression of IAPs (Inhibitory of Apoptosis Proteins) and of their alternative splice variants in hepatocellular carcinoma tissues and cells 79
Use of herbal products among cancer and transplanted patients in the town of Palermo,Sicily. 78
Antitumor effects of curcumin in human hepatic cancer cells: Analysis of their relationship to inhibition of NF-kB and pro-survival gene expression. 77
Plant polyphenols as possible lead compound against hormone-independent multidrug resistant breast cancer. 76
“Antitumor and molecular effects of curcumin and of its isoxazole analogue on multidrug resistant breast cancer cells. New perspectives in tumor theraphy: molecular aspects, 2006”. 76
The evolution of European Medicines Agency drug approval: the adaptive licensing 75
High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. 74
Antitumor effects of curcumin, alone or in combination with cisplatin, on hepatic cancer cells. Analysis of their relationship to IL-6 production 73
Antitumor effects of the NF-kB inhibitors curcumin and DHMEQ, alone or combined with cisplatin, on hepatic cancer cells. analysis of their relationship to IL-6 production. 72
Epigenetic agents as an adjunct to active chemotherapy in hematological tumor cell lines 72
Raf-1 Kinase Inhibitor Protein down-regulation in hepatocellular carcinoma: investigation of possible mechanisms 71
Possible pharmacological interaction between corticosteroids and a calcineurin inhibitor (tacrolimus) in liver transplant patients. 68
null 67
Gli effetti indesiderati dei farmaci 66
The antitumor activities of curcumin and of its novel isoxazole analogue MR 39 are not hampered by the multidrug resistant condition of tumor cells expressing both P-glycoprotein and different inhibitory of apoptosis proteins 66
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells 66
Anticancer drugs and pharmacovigilance: the Sicilian regional program 66
RUOLO DELL’ECOCOLOR DOPPLER TISSUTALE NELLA VALUTAZIONE DELLA CARDIOTOSSICITÀ DA CHEMIOTERAPICI 66
Effetti della curcumina e del suo derivato isossazolico in modelli di neoplasia multifarmacoresistente 65
Antitumor effects of the grape stilbenes resveratrol and piceatannol on multidrug and apoptosis resistant HL60 leukemia cells" 65
Le attività antitumorali della curcumina e del suo più potente analogo isossazolico non sono compromesse dal pattern di espressione genica della variante MDR della linea di carcinoma mammario MCF-7 65
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells 63
ELABORATION OF CURCUMIN INTO DIKETONE MODIFIED ANALOGUES DEVOID OF NUCLEOPHILIC ADDITION CAPABILITY; IMPLICATIONS FOR THEIR ANTITUMOR AND CHEMOSENSITIZING ACTIVITIES 63
Antitumor effects of novel co-drugs linking histone deacetylase and ribonucleotide reductase inhibitors in hematological tumors 63
Farmacovigilanza in oncologia: l'esperienza di un centro dedicato nella Regione Sicilia 63
DISTRIBUTION OF CYP3A5 AND MDR-1 SINGLE NUCLEOTIDE POLYMORPHISMS IN CAUCASIAN LIVER TRANSPLANT PATIENTS 61
Ihnibitor of Apoptosis Proteins (IAPs) as a new possible therapeutic targets in hepatocellular cancer. 60
Possible mechanisms of Raf-1 Kinase Inhibitor Protein down-regulation in hepatocellular carcinoma 60
Effects of curcumin and related analogues on tumor cell lines expressing multiple mechanisms of drug resistance 59
Restoration of Raf-1 Kinase Inhibitor Protein levels as a possible therapeutic approach in hepatocellular carcinoma. 59
Farmacovigilanza attiva sul ruolo dei farmaci antiangiogenetici nell’osteonecrosi dei mascellari 59
FARMACI INIBITORI DELLE TOPOISOMERASI 59
Totale 10.326
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.095
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.095
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.164 0 0 167 192 278 342 300 162 291 137 169 126
2020/20211.490 59 159 94 161 162 47 151 69 202 74 160 152
2021/20221.418 37 342 39 29 81 46 97 60 156 173 73 285
2022/20231.799 187 261 28 179 231 298 187 122 204 13 71 18
2023/2024920 56 163 69 68 60 182 75 61 9 27 22 128
2024/2025292 46 167 79 0 0 0 0 0 0 0 0 0
Totale 11.942